PT  - JOURNAL ARTICLE
AU  - HIBI, KENJI
AU  - SAKATA, MAKIKO
AU  - YOKOMIZO, KAZUAKI
AU  - KITAMURA, YO-HEI
AU  - SAKURABA, KAZUMA
AU  - SHIRAHATA, ATSUSHI
AU  - GOTO, TETSUHIRO
AU  - MIZUKAMI, HIROKI
AU  - SAITO, MITSUO
AU  - ISHIBASHI, KAZUYOSHI
AU  - KIGAWA, GAKU
AU  - NEMOTO, HIROSHI
AU  - SANADA, YUTAKA
TI  - Methylation of the <em>MGMT</em> Gene is Frequently Detected in Advanced Gastric Carcinoma
DP  - 2009 Dec 01
TA  - Anticancer Research
PG  - 5053--5055
VI  - 29
IP  - 12
4099  - http://ar.iiarjournals.org/content/29/12/5053.short
4100  - http://ar.iiarjournals.org/content/29/12/5053.full
SO  - Anticancer Res2009 Dec 01; 29
AB  - Background: Recently, Herfarth et al. reported that a subset of colorectal tumors was characterized by a specific methylation pattern in the MGMT promoter associated with reduced MGMT expression. Materials and Methods: Methylation status of the MGMT gene was examined in primary carcinomas and the corresponding normal tissues derived from 38 patients with gastric cancer using quantitative methylation-specific PCR (qMSP) and the correlation between the methylation status and the clinicopathological findings was evaluated. Results: Aberrant methylation of the MGMT gene was detected in 4 out of the 38 (11%) primary gastric carcinomas, suggesting that the methylation of MGMT is observed in gastric carcinomas as well as colorectal ones. The clinicopathological data were correlated with the methylation results. A significant difference was observed in the extent of tumor (p=0.0470), lymph node metastasis (p=0.0470), and TNM stage (p=0.0377) (Table I). Moreover, a trend was shown toward large maximal tumor size in methylated tumors (p=0.134). Conclusion: MGMT was more frequently methylated in advanced gastric carcinomas.